Ashish M. Kamat

Sep 30, 2024 | europeanurology.com | Roger Li |Joshua A. Linscott |James Catto |Joshua J. Meeks |Siamak Daneshmand |Bishoy M Faltas | +4 more

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USAbDepartment of Immunology, H.

Jul 2, 2024 | nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph. This correction has been made to the HTML and PDF versions of the article. About this articleLi, R., Shah, P.H., Stewart, T.F. et al.

Jun 18, 2024 | nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024In the version of the article initially published, the text “Immune-related adverse effects were exclusively associated with pembrolizumab” and, in the following sentence, also referring to adverse effects, “…all related to pembrolizumab” has been removed from the Abstract.

Jun 6, 2024 | nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat

AbstractCretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus Calmette–Guérin (BCG)-experienced non-muscle-invasive bladder cancer.

Jul 14, 2023 | urotoday.com | Ashish M. Kamat

This website uses cookies to ensure you get the best experience on our website. Privacy Policy Published 14 July 2023 Bladder cancer can be seen as a chronic condition—patients with nonmetastatic disease can live years, even decades, after diagnosis, and they often die of unrelated causes.1 This chronicity intensifies the impacts of initial management: Clinical decisions made in the first weeks or months of the patient’s journey exert a domino effect that spans the entire disease trajectory.